BioRestorative Therapies, Inc.
BRTX
Rank in Stocks
#32003
BioRestorative Therapies, Inc. is a life sciences company dedicated to... BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Share Price
$1.60
Last synced: 2026-11-09
Market Cap
$2.21M
Change (1 day)
5.26%
Change (1 year)
13.48%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioRestorative Therapies, Inc. (BRTX)
Category
Healthcare
EPS for BioRestorative Therapies, Inc. (BRTX)
EPS as of March 2026 TTM: $-22.20
According to BioRestorative Therapies, Inc.'s latest financial reports, its current EPS (TTM) is $-22.20. At the end of 2025 the company had an EPS of $-31.60, a decrease compared to its 2024 EPS of $-23.20.
EPS history for BioRestorative Therapies, Inc. from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-22.20 | -29.75% |
| 2025 | $-31.60 | 36.21% |
| 2024 | $-23.20 | -53.04% |
| 2023 | $-49.40 | -32.33% |
| 2022 | $-73.00 | -90.21% |
| 2021 | $-746.00 | 30.60% |
| 2020 | $-571.20 | -98.91% |
| 2019 | $-52.60K | -59.92% |
| 2018 | $-131.25K | -5.71% |
| 2017 | $-139.20K | -17.14% |
| 2016 | $-168.00K | -34.38% |
| 2015 | $-256.00K | -27.27% |
| 2014 | $-352.00K | -37.14% |
| 2013 | $-560.00K | -30.00% |
| 2012 | $-800.00K | 0.00% |
| 2011 | $-800.00K | 99,900.00% |
| 2010 | $-800.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -170.54% |
US
|
|
| $-7.07 | -68.15% |
US
|
|
| $-5.29 | -76.17% |
AU
|
|
| $12.88 | -158.02% |
BE
|
|
| $21.56 | -197.12% |
NL
|
Questions about BioRestorative Therapies, Inc.'s earnings per share (EPS)
What is BioRestorative Therapies, Inc.'s earnings per share (EPS)?
BioRestorative Therapies, Inc.'s earnings per share (EPS) over the last twelve months is $-22.20, as of Mar 2026.
What was BioRestorative Therapies, Inc.'s earnings per share (EPS) in 2025?
In 2025, BioRestorative Therapies, Inc.'s earnings per share (EPS) was $-31.60, compared with $-23.20 in 2024.
How has BioRestorative Therapies, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioRestorative Therapies, Inc.'s earnings per share (EPS) was highest in 2024 ($-23.20) and lowest in 2021 ($-746.00).
How does BioRestorative Therapies, Inc.'s earnings per share (EPS) compare with similar companies?
BioRestorative Therapies, Inc.'s earnings per share (EPS) ($-22.20) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.